As per the new market report published by Factor & Equilibrium (www.factorandequilibrium.com) “Alzheimer’s Drugs Market – Global Industry Insights Market Size, Estimation and Growth Forecast, By Drug Class (Cholinergic, Memantine, Combined Drug and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Stores), & By Regions, 2017 – 2025” is expected to reach USD 5,069.2 Million by 2025 in terms of revenue. In 2016, the market was valued USD 2,839.4 Million in terms of revenue.
Browse 20 Data Tables and 29 Figures in the full report at https://www.factorandequilibrium.com/market-report/diamond-semiconductor-substrates-market-analysis
Alzheimer’s is a progressive disease. It is essentially a type of dementia (decline in mental ability or memory loss). Alzheimer’s is a type of disease that causes problems with memory, behavior and thinking. The symptoms of the disease typically develop slowly (progressive disease) and get worse over time, and gradually interfere with daily tasks. Alzheimer’s drugs market is primarily driven by global rise in prevalence of Alzheimer’s disease, and growing awareness about the treatment of the disease. By drug class the global Alzheimer’s drugs market can be segmented into cholinergic, memantine, combined drug and others. The market can be further divided by distribution channel into hospital pharmacy, retail pharmacy and online stores.
The increasing prevalence of several neurodegenerative diseases especially in the developing countries is expected to fuel the growth of Alzheimer’s drug market size.
By drug class the global Alzheimer’s drugs market can be segmented into cholinergic, memantine, combined drug and others. Memantine is projected to dominate the market share of the Alzheimer’s drugs market in the future. Lack of effective classes of drugs in the developing regions is one of the prime factors for the dominance of this drug class.
In terms of revenue, memantine was the largest drug class in Alzheimer’s drugs market in 2016
By distribution channel, the Alzheimer’s drugs market has been segmented into hospital pharmacy, retail pharmacy and online stores. The hospital pharmacy segment is likely to hold a leading position in the global Alzheimer’s drugs market. Increasing prevalence and awareness of the disease is likely to give rise to more and more patients that get admitted in hospitals or go for a check-up in hospitals. Since the disease is progressive in nature, patient’s confidence is expected to be more in hospital treatments, thereby resulting into high sales in the hospital pharmacies.
In terms of revenue, hospital pharmacies was the largest by growth method in Alzheimer’s drugs market in 2016
Combined drug treatment is expected to remain a major driver to the global Alzheimer’s drugs market in the future owing to the growing recognition of its effectiveness and increasing availability across the world, especially in the developed countries.
Inquiry before Buying: https://www.factorandequilibrium.com/inquire-before-buy
The global Alzheimer’s drugs market has been segment into five key geographical regions: North America, Europe, Asia-Pacific, Middle East and Africa and South America.
North America is likely to be the dominant region in the global Alzheimer’s drugs market. Rising prevalence of the disease across the region as well as presence of large global players, thereby making distribution easier in the region, are the some of the major factors that are likely to augment the growth of the market in this region. Nonetheless, Europe and Asia-Pacific has immense potential for expansion, owing to growing geriatric population, and rising awareness about the disease in the developing regions. African region is expected to register a moderate growth rate owing to lack of awareness about the disease in the region. Asia-Pacific is likely to grow at a considerable rate, showing a robust CAGR during the forecast period.
North America generated the largest revenue share of the market in 2016.
Leading Player Mapping
The global Alzheimer’s drug industry is characterized by the presence of various large and small vendors across the globe. Some of the major manufactures of Alzheimer’s drug includes H Lundbeck A/S (Denmark), Ono Pharmaceutical (Japan), Eisai Co Ltd. (Japan) and Johnson & Johnson (The U.S) among others.
Browse Related Upcoming Reports: https://www.factorandequilibrium.com/market-research/semiconductors-and-electronics-market
The market has been segmented as follows:
Alzheimer’s Drugs Market: By Drug Class
- Combined Drug
Alzheimer’s Drugs Market: By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Stores
Alzheimer’s Drugs Market: By Geography
- North America (U.S. and Canada)
- Europe (U.K., Germany, France, CIS + Scandinavia and Rest of Europe)
- Asia-Pacific (China, Japan, India, South Korea and Rest of Asia-Pacific)
- Middle East and Africa (Israel, South Africa and Rest of Middle East and Africa)
- South America (Brazil, Mexico and Rest of South America)
About Factor & Equilibrium
Factor & Equilibrium is a leading market research and strategy consulting firm. We specialize in helping clients to identify market trends, business opportunities and develop growth strategies. Factor & Equilibrium has engagement model to identify requirements of clients efficiently. We offer premium research studies across different industry verticals including chemicals and materials, semiconductors & electronics, healthcare and food & beverages.
We work as market research and consulting partner for government agencies, companies and research institutes having presence across different countries globally. We are knowledge partner of leading players operating in different industries such as chemicals and materials, semiconductors & electronics, healthcare and food & beverages.
Factor & Equilibrium
New York City, NY
Company Name: Factor & Equilibrium
Contact Person: Arupratan Chattopadhyay, Marketing Manager
Email: Send Email
City: New York City
State: NY 10017
Country: United States